Brain Cancer Treatment Doubles Survival in Major Trial

Brain cancer patients now have a treatment option that could give them years, not months, thanks to a breakthrough approach that delivers radiation during surgery instead of weeks later.

The phase III ROADS trial tested a revolutionary technique where doctors implant tiny radiation tiles directly into the surgical site after removing a brain tumor. These small collagen tiles, embedded with titanium-encapsulated radioactive seeds, deliver targeted radiation right where it's needed most.

The results stunned researchers at the 2026 ASCO Annual Meeting. Patients who received the tile-based therapy lived a median of 42.5 months compared to just 17.6 months for those who got standard radiation weeks after surgery. That's more than double the survival time.

Dr. Jeffrey Weinberg from MD Anderson Cancer Center explained the problem this new approach solves. "Patients undergoing tumor resection currently face an inherent gap in care: Radiation is delayed for weeks after surgery," he said. During that waiting period, cancer can regrow and other treatments get delayed.

The study included 204 patients from 32 medical centers with newly diagnosed brain metastases. Half received the new tile therapy during their initial surgery, while half were scheduled for standard stereotactic radiation 2 to 4 weeks later.

Beyond survival, the tiles virtually eliminated tumor recurrence at the surgical site. Only 1% of patients who got tile therapy saw their cancer return in that spot, compared to nearly 12% who received delayed radiation. At the 12-month mark, recurrence rates were 1.3% versus 15.4%.

The Bright Side

The tiles solve a real-world problem that affects one in five patients. In the study, 18 patients assigned to get standard radiation never received it. Insurance issues, weather events, prolonged recovery, or simple logistics got in the way. With tile therapy, patients are guaranteed to receive their radiation because it happens during the surgery they're already having.

The safety profile matched standard treatment, with no increase in side effects. Quality of life measures remained similar between both groups. The tiles deliver about 100 to 120 Gray of highly focused radiation to the surgical cavity wall, with 90% delivered within five weeks.

Dr. David Schiff from the University of Virginia called the approach a potential game-changer. "If this proof of concept holds, it would largely supplant cavity radiosurgery for this indication," he said.

The FDA has already cleared the tile-based system for use, meaning eligible patients can access this treatment now rather than waiting years for approval.

For thousands of patients facing one of medicine's most challenging diagnoses, this innovation transforms weeks of uncertainty into immediate hope and significantly more time with loved ones.